A Prospective, Multi-site Clinical Study to Collect User Feedback Using Affirm® Contrast Biopsy

NACompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 5, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

August 18, 2022

Conditions
Breast Cancer
Interventions
DEVICE

Affirm Contrast Biopsy procedure

Contrast Enhanced Digital Mammography (CEDM) is an extension of the existing indication for diagnostic mammography with the Selenia Dimensions system and 3Dimensions system. Biopsy targeting can be done on captured contrast enhanced images (scout and stereo pair). The CEDM application shall enable contrast enhanced breast imaging using a dual energy technique. This imaging technique can be used as an adjunct following mammography and/or ultrasound exams to localize a known or suspected lesion. Affirm Contrast Biopsy is intended for patients recommended for biopsy who have had a suspicious finding on previous contrast enhanced imaging or have lesions that may be occult under other modalities.

Trial Locations (2)

15213

University of Pittsburgh Medical Center, Pittsburgh

85054

Mayo Clinic, Phoenix

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hologic, Inc.

INDUSTRY